Login to Your Account



Pharma: Other News To Note


Friday, September 14, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it started an open-label U.S. expanded access program for investigational oncology compound afatinib, which will be available to eligible patients with locally advanced or metastatic non-small-cell lung cancer who have an epidermal growth factor receptor mutation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription